A Phase I/II Trial of Bendamustine/Treanda, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)

Trial Profile

A Phase I/II Trial of Bendamustine/Treanda, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Bendamustine (Primary) ; Carboplatin; Etoposide; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Acronyms TREC
  • Most Recent Events

    • 24 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 15 Nov 2013 Planned end date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top